# Thymogen IM862: nasal drops in AIDS-related Kaposi's sarcoma

Source: https://pepvault.app/research/thymogen-tulpule-2000

Last updated: 2026-11-18

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Research](https://pepvault.app/research) [Thymogen](https://pepvault.app/research#thymogen)

Randomized trial · people

# Thymogen (IM862): 36% major responses in AIDS-related Kaposi's sarcoma

Checked against the paper November 2026 Randomized trial [Published by PepVault](https://pepvault.app/guides/how-we-research)

## The takeaway

This early human trial links the Glu-Trp dipeptide, given as IM862 nose drops, to tumor responses and mild side effects in AIDS-related Kaposi's sarcoma, but it lacked a placebo comparison, and a later placebo-controlled trial found IM862 no better than placebo.

- **Kind:** Randomized trial
- **Studied in:** People
- **Published:** 2000
- **Journal:** J Clin Oncol

## What they tested

The team tested whether IM862, a natural peptide the authors describe as blocking new blood vessel growth, given as nose drops, was tolerable and had any effect on Kaposi's sarcoma tied to AIDS.

## How the study was done

A randomized phase II trial in adults with AIDS-related Kaposi's sarcoma, almost all of them men, compared two schedules of 5 mg nasal drops: 5 days on and 5 days off (18 patients) or every other day (26 patients), with no placebo group. Treatment ran in cycles until the disease grew or side effects became too much, and 75% had already had chemotherapy.

<!--promo-->

PepVault for iPhone

## Taking thymogen? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## What they found

Among the patients, 36% had a major response: 5 had a complete remission (tumors cleared) and 11 a partial remission (tumors shrank). Responses showed up after a median of 6 weeks and lasted a median of 33+ weeks, ranging from 12+ to 95+ weeks. Other patients had stable disease for 7 to 72+ weeks. Side effects were mild, short-lived headache, fatigue, tingling and nausea, with no blood-related side effects tied to treatment.

## What it doesn’t show

This was a small trial with no placebo or untreated group, so it can't show how much of the effect came from IM862 itself. All but 5 patients were also taking protease inhibitors at the same time. A later, larger placebo-controlled trial of IM862 in the same disease found it no better than placebo.

## The paper

Tulpule et al. Results of a randomized study of IM862 nasal solution in the treatment of AIDS-related Kaposi's sarcoma. J Clin Oncol. 2000.

- [PubMed (PMID 10673512)](https://pubmed.ncbi.nlm.nih.gov/10673512/)
- [The paper (DOI 10.1200/JCO.2000.18.4.716)](https://doi.org/10.1200/JCO.2000.18.4.716)

## The compound

- [Thymogen: how it works, half-life, studied range and evidence](https://pepvault.app/peptides/thymogen)

## With this study

### Thymogen

- [Thymogen: the full reference](https://pepvault.app/peptides/thymogen)

### Studies

- [Thymogen (IM862): 8 of 25 kidney cancer patients had stable disease](https://pepvault.app/research/thymogen-deplanque-2004)
- [All 2 studies](https://pepvault.app/research#thymogen)

### Compared with

- [Thymalin vs Thymogen](https://pepvault.app/peptides/compare/thymalin-vs-thymogen)

### Tools

- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)

### Terms on this page

- [Peptide](https://pepvault.app/glossary/peptide)
- [Cycle](https://pepvault.app/glossary/cycle)
- [Placebo](https://pepvault.app/glossary/placebo)

## More studies on Thymogen

- [Thymogen (IM862): 8 of 25 kidney cancer patients had stable disease](https://pepvault.app/research/thymogen-deplanque-2004) Clinical trial · people · 2004
- [Every study on Thymogen](https://pepvault.app/research#thymogen)

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed November 2026. Spot an error? [feedback@pepvault.app](mailto:feedback@pepvault.app). [How we research](https://pepvault.app/guides/how-we-research). This page reports one study; it is not medical advice.

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-next&mt=8)

<!--/promo-->

<!--promo-->

PepVault for iPhone

## Taking thymogen? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

<!--promo-->

PepVault for iPhone

## Taking thymogen? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## With this study

### Thymogen

- [Thymogen: the full reference](https://pepvault.app/peptides/thymogen)

### Studies

- [Thymogen (IM862): 8 of 25 kidney cancer patients had stable disease](https://pepvault.app/research/thymogen-deplanque-2004)
- [All 2 studies](https://pepvault.app/research#thymogen)

### Compared with

- [Thymalin vs Thymogen](https://pepvault.app/peptides/compare/thymalin-vs-thymogen)

### Tools

- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)

### Terms on this page

- [Peptide](https://pepvault.app/glossary/peptide)
- [Cycle](https://pepvault.app/glossary/cycle)
- [Placebo](https://pepvault.app/glossary/placebo)

<!--promo-->

PepVault for iPhone

## Taking thymogen? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## Research

- [All studies](https://pepvault.app/research)
- [Every study on Thymogen](https://pepvault.app/research#thymogen)

## The library

- [Thymogen](https://pepvault.app/peptides/thymogen)
- [The peptide reference library](https://pepvault.app/peptides)

## How we work

- [How we research](https://pepvault.app/guides/how-we-research)
- [How we check the library](https://pepvault.app/about#library)

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
